An Open-Label, 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet.
Phase of Trial: Phase I
Latest Information Update: 29 Jan 2015
At a glance
- Drugs Apitolisib (Primary) ; Rabeprazole
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors Genentech
- 22 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Feb 2011 New trial record